JP2024532886A - ヒトＣＤ１６ａに対する抗体及びその変異体 - Google Patents

ヒトＣＤ１６ａに対する抗体及びその変異体 Download PDF

Info

Publication number
JP2024532886A
JP2024532886A JP2024512952A JP2024512952A JP2024532886A JP 2024532886 A JP2024532886 A JP 2024532886A JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024532886 A JP2024532886 A JP 2024532886A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding portion
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532886A5 (https=
JPWO2023025215A5 (https=
Inventor
カン、リウ
ヂョンダオ、リ
ヂィーフェイ、ザオ
クイイェン、シャオ
ビン、リウ
イ、ジン
リウソン、イン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of JP2024532886A publication Critical patent/JP2024532886A/ja
Publication of JP2024532886A5 publication Critical patent/JP2024532886A5/ja
Publication of JPWO2023025215A5 publication Critical patent/JPWO2023025215A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024512952A 2021-08-25 2022-08-25 ヒトＣＤ１６ａに対する抗体及びその変異体 Pending JP2024532886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021114549 2021-08-25
CNPCT/CN2021/114549 2021-08-25
PCT/CN2022/114642 WO2023025215A1 (en) 2021-08-25 2022-08-25 ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a

Publications (3)

Publication Number Publication Date
JP2024532886A true JP2024532886A (ja) 2024-09-10
JP2024532886A5 JP2024532886A5 (https=) 2025-09-01
JPWO2023025215A5 JPWO2023025215A5 (https=) 2025-09-01

Family

ID=85321557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512952A Pending JP2024532886A (ja) 2021-08-25 2022-08-25 ヒトＣＤ１６ａに対する抗体及びその変異体

Country Status (6)

Country Link
US (1) US20240352128A1 (https=)
EP (1) EP4392453A4 (https=)
JP (1) JP2024532886A (https=)
KR (1) KR20240049331A (https=)
CN (1) CN117858902A (https=)
WO (1) WO2023025215A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813603A (zh) * 2023-03-03 2025-10-17 广州百济神州生物制药有限公司 Cd16a抗体和使用方法
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
WO2024206126A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
CN120025439B (zh) * 2023-11-21 2026-04-17 南京融捷康生物科技有限公司 一种抗CD16a的单域抗体及其用途
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
WO2018039626A1 (en) * 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
CN110461357A (zh) * 2017-02-28 2019-11-15 阿菲姆德股份有限公司 抗cd16a抗体与细胞因子的组合
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途

Also Published As

Publication number Publication date
CN117858902A (zh) 2024-04-09
US20240352128A1 (en) 2024-10-24
KR20240049331A (ko) 2024-04-16
EP4392453A4 (en) 2025-10-08
WO2023025215A1 (en) 2023-03-02
EP4392453A1 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
AU2019274656B2 (en) Anti-CD3 antibodies and uses thereof
AU2019243665B2 (en) Multivalent antibody
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
CN111094350B (zh) 调节由细胞表达的生物活性的抗体
JP2024532886A (ja) ヒトＣＤ１６ａに対する抗体及びその変異体
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
AU2019326635B2 (en) Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
JP2009529920A (ja) Ｒａｇｅの拮抗作用のための方法および組成物
JP2021522347A (ja) Ｐｄ−１およびｌａｇ−３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
CN113527493B (zh) 一种b7-h3抗体及其应用
TW202340248A (zh) 促效性ｌｔｂｒ抗體及包含其之雙特異性抗體
CN120424213A (zh) 特异性结合pd-1的单克隆抗体及其医药用途
WO2025077834A1 (en) Anti-il-4ra antibodies and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
WO2025255558A2 (en) Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
KR20260016889A (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
HK40065826A (zh) 抗dll3嵌合抗原受体及其用途
HK40098926A (zh) 一种抗dll3嵌合抗原受体及其用途
CA3161390A1 (en) Antibodies binding to hla-a2/mage-a4
CN116888156A (zh) 非阻断性人ccr8结合剂
HK40065826B (zh) 抗dll3嵌合抗原受体及其用途
HK40044020A (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250821